Renal complications and quality of life in postsurgical hypoparathyroidism: a case-control study.
Calcium
/ blood
Calcium-Regulating Hormones and Agents
/ metabolism
Female
Humans
Hypocalcemia
/ blood
Hypoparathyroidism
/ blood
Male
Middle Aged
Nephrolithiasis
/ blood
Outcome Assessment, Health Care
Postoperative Complications
/ blood
Quality of Life
Surveys and Questionnaires
Thyroid Neoplasms
/ pathology
Thyroidectomy
/ adverse effects
Vitamin D
/ therapeutic use
Calcitriol
Calcium carbonate
Nephrolithiasis
QoL
Renal ultrasounds
SF-36
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
28
07
2021
accepted:
27
09
2021
pubmed:
13
10
2021
medline:
24
3
2022
entrez:
12
10
2021
Statut:
ppublish
Résumé
Conventional therapy (calcium and activated vitamin D) does not restore calcium homeostasis in patients with chronic hypoparathyroidism (HypoPT) and is associated with renal complications and reduced quality of life (QoL). The aim of this study was to evaluate in a case-control, cross-sectional study, the rate of renal complications and QoL in two sex- and age-matched cohort of patients with differentiated thyroid cancer with (n = 89) and without (n = 89) chronic post-operative HypoPT (PoHypoPT) and their relationship with the biochemical control of the disease. Serum and urinary parameters, renal ultrasound and QoL were assessed by SF-36 and WHO-5 questionnaires. Forty-three (48.3%) PoHypoPT patients reported symptoms of hypocalcemia. Twenty-six (29.2%) patients were at target for all 6 parameters, 46 (51.6%) for 5. The most frequently unmet targets were gender-specific 24-h urinary calcium (44.9%) and serum calcium (37.1%). Serum phosphate, magnesium and 25(OH)D were in the normal range in > 90% of patients. Renal calcifications were found in 26 (29.2%) patients, with no correlation with 24-h urinary calcium. eGFR did not differ between patients and controls. Conversely, patients had a significant higher rate of renal calcifications and a lower SF-36, but not WHO-5, scores. SF-36 scores did not differ between PoHypoPT patients who were, or not, hypocalcemic. Our study shows that the rate of renal calcifications was higher in patients with PoHypoPT than in those without. This finding, together with the reduced QoL and the presence of hypocalcemic symptoms in about half patients, underscores that the treatment of chronic HypoPT with conventional therapy is suboptimal.
Identifiants
pubmed: 34637114
doi: 10.1007/s40618-021-01686-2
pii: 10.1007/s40618-021-01686-2
doi:
Substances chimiques
Calcium-Regulating Hormones and Agents
0
Vitamin D
1406-16-2
Calcium
SY7Q814VUP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
573-582Subventions
Organisme : the italian ministry of university and research
ID : PRIN 2017-HBHA98
Organisme : takeda pharmaceutical company
ID : Investigator-initiated research ID IIR-ITA-001335
Informations de copyright
© 2021. Italian Society of Endocrinology (SIE).
Références
Food and Drugs Administration NATPARA:shire-NPS Pharmaceuticals, Inc, 2015. www.fda.gov/medwatch . Accessed 13 Apr 2021
European Medicine Agency (2017) First hormone replacement therapy for hypoparathyroidism
Bollerslev J, Rejnmark L, Marcocci C et al (2015) European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. J Clin Endocrinol Metab 173:G1–G20. https://doi.org/10.1530/EJE-15-0628
doi: 10.1530/EJE-15-0628
Brandi ML, Bilezikian JP, Shoback D et al (2016) Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab 101:2273–2283. https://doi.org/10.1210/jc.2015-3907
doi: 10.1210/jc.2015-3907
pubmed: 26943719
Bilezikian JP, Brandi ML, Cusano NE et al (2016) Management of hypoparathyroidism: present and future. J Clin Endocrinol Metab 101:2313–2324. https://doi.org/10.1210/jc.2015-3910
doi: 10.1210/jc.2015-3910
pubmed: 26938200
pmcid: 5393596
Mitchell DM, Regan S, Cooley MR et al (2012) Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab 97:4507–4514. https://doi.org/10.1210/jc.2012-1808
doi: 10.1210/jc.2012-1808
pubmed: 23043192
pmcid: 3513540
Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2013) Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res 28:2277–2285. https://doi.org/10.1002/jbmr.1979
doi: 10.1002/jbmr.1979
pubmed: 23661265
Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2014) Postsurgical hypoparathyroidism-risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res 29:2504–2510. https://doi.org/10.1002/jbmr.2273
doi: 10.1002/jbmr.2273
pubmed: 24806578
Underbjerg L, Sikjaer T, Rejnmark L (2018) Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study. J Bone Miner Res 33:822–831. https://doi.org/10.1002/jbmr.3368
doi: 10.1002/jbmr.3368
pubmed: 29281760
Gosmanova EO, Chen K, Rejnmark L et al (2021) Risk of chronic kidney disease and estimated glomerular filtration rate decline in patients with chronic hypoparathyroidism: a retrospective cohort study. Adv Ther 38:1876. https://doi.org/10.1007/S12325-021-01658-1
doi: 10.1007/S12325-021-01658-1
pubmed: 33687651
pmcid: 8004481
Ridder LO, Harsløf T, Sikjær T et al (2021) Determinants of hypercalciuria and renal calcifications in chronic hypoparathyroidism: a cross-sectional study. Clin Endocrinol (Oxf). https://doi.org/10.1111/cen.14470
doi: 10.1111/cen.14470
Meola A, Vignali E, Matrone A et al (2018) Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Invest 41:1221–1226. https://doi.org/10.1007/s40618-018-0857-5
doi: 10.1007/s40618-018-0857-5
pubmed: 29516386
Hamdy NAT, Decallonne B, Evenepoel P et al (2020) Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey. J Endocrinol Investig 447(44):1437–1446. https://doi.org/10.1007/S40618-020-01442-Y
doi: 10.1007/S40618-020-01442-Y
Hadker N, Egan J, Sanders J et al (2014) Understanding the burden of illness associated with hypoparathyroidism reported among patients in the paradox study. Endocr Pract 20:671–679. https://doi.org/10.4158/EP13328.OR
doi: 10.4158/EP13328.OR
pubmed: 24449664
Büttner M, Locati LD, Pinto M et al (2020) Quality of life in patients with hypoparathyroidism after treatment for thyroid cancer. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgaa597
doi: 10.1210/clinem/dgaa597
pubmed: 32918085
Siggelkow H, Clarke BL, Germak J et al (2020) Burden of illness in not adequately controlled chronic hypoparathyroidism: findings from a 13-country patient and caregiver survey. Clin Endocrinol (Oxf) 92:159–168. https://doi.org/10.1111/cen.14128
doi: 10.1111/cen.14128
Astor MC, Løvas K, Debowska A et al (2016) Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J Clin Endocrinol Metab 101:3045–3053. https://doi.org/10.1210/jc.2016-1477
doi: 10.1210/jc.2016-1477
pubmed: 27186861
pmcid: 4971340
Sikjaer T, Rolighed L, Hess A et al (2014) Effects of PTH(1–84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int 25:1717–1726. https://doi.org/10.1007/s00198-014-2677-6
doi: 10.1007/s00198-014-2677-6
pubmed: 24687385
Cusano NE, Rubin MR, McMahon DJ et al (2014) PTH(1–84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocrinol Metab 99:3694–3699. https://doi.org/10.1210/jc.2014-2267
doi: 10.1210/jc.2014-2267
pubmed: 24978675
pmcid: 4184077
Arlt W, Fremerey C, Callies F et al (2002) Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol 146:215–222. https://doi.org/10.1530/eje.0.1460215
doi: 10.1530/eje.0.1460215
pubmed: 11834431
Sikjaer T, Moser E, Rolighed L et al (2016) Concurrent hypoparathyroidism is associated with impaired physical function and quality of life in hypothyroidism. J Bone Miner Res 31:1440–1448. https://doi.org/10.1002/jbmr.2812
doi: 10.1002/jbmr.2812
pubmed: 26865527
Cummings SR, Block G, McHenry K, Baron RB (1987) Evaluation of two food frequency methods of measuring dietary calcium intake. Am J Epidemiol 126:796–802. https://doi.org/10.1093/OXFORDJOURNALS.AJE.A114716
doi: 10.1093/OXFORDJOURNALS.AJE.A114716
pubmed: 3661527
Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
doi: 10.7326/0003-4819-150-9-200905050-00006
pubmed: 19414839
pmcid: 2763564
Saponaro F, Cetani F, Mazoni L et al (2020) Hypercalciuria: its value as a predictive risk factor for nephrolithiasis in asymptomatic primary hyperparathyroidism? J Endocrinol Invest 43:677–682. https://doi.org/10.1007/s40618-019-01162-y
doi: 10.1007/s40618-019-01162-y
pubmed: 31873910
Topp CW, Østergaard SD, Søndergaard S, Bech P (2015) The WHO-5 well-being index: a systematic review of the literature. Psychother Psychosom 84:167–176. https://doi.org/10.1159/000376585
doi: 10.1159/000376585
pubmed: 25831962
Khan AA, AbuAlrob H, Punthakee Z et al (2021) Canadian national hypoparathyroidism registry: an overview of hypoparathyroidism in Canada. Endocrine. https://doi.org/10.1007/s12020-021-02629-w
doi: 10.1007/s12020-021-02629-w
pubmed: 34120313
Akkan T, Dagdeviren M, Koca AO et al (2020) Alternate-day calcium dosing may be an effective treatment option for chronic hypoparathyroidism. J Endocrinol Investig 436(43):853–858. https://doi.org/10.1007/S40618-019-01173-9
doi: 10.1007/S40618-019-01173-9
Chen KS, Gosmanova EO, Curhan GC et al (2020) Five-year estimated glomerular filtration rate in patients with hypoparathyroidism treated with and without rhPTH(1–84). J Clin Endocrinol Metab 105:1–9. https://doi.org/10.1210/clinem/dgaa490
doi: 10.1210/clinem/dgaa490
Eknoyan G, Levin A, Levin NW (2003) Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:1–201. https://doi.org/10.1016/s0272-6386(03)00905-3
doi: 10.1016/s0272-6386(03)00905-3
David K, Moyson C, Vanderschueren D, Decallonne B (2019) Long-term complications in patients with chronic Hypoparathyroidism: a cross-sectional study. Eur J Endocrinol 180:71–78. https://doi.org/10.1530/EJE-18-0580
doi: 10.1530/EJE-18-0580
pubmed: 30407920
Lopes MP, Kliemann BS, Bini IB et al (2016) Hypoparathyroidism and pseudohypoparathyroidism: etiology, laboratory features and complications. Arch Endocrinol Metab 60:532–536. https://doi.org/10.1590/2359-3997000000221
doi: 10.1590/2359-3997000000221
pubmed: 27901178
Ketteler M, Chen K, Gosmanova EO et al (2021) Risk of nephrolithiasis and nephrocalcinosis in patients with chronic hypoparathyroidism: a retrospective cohort study. Adv Ther 38:1946–1957. https://doi.org/10.1007/s12325-021-01649-2
doi: 10.1007/s12325-021-01649-2
pubmed: 33704680
pmcid: 8004511
Saponaro F, Marcocci C, Apicella M et al (2020) Hypomagnesuria is associated with nephrolithiasis in patients with asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgaa233
doi: 10.1210/clinem/dgaa233
pubmed: 32369583
Cusano NE, Rubin MR, McMahon DJ et al (2013) The effect of PTH(1–84) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab 98:2356–2361. https://doi.org/10.1210/jc.2013-1239
doi: 10.1210/jc.2013-1239
pubmed: 23596139
pmcid: 3667253
Bagó AG, Dimitrov E, Saunders R et al (2009) Parathyroid hormone 2 receptor and its endogenous ligand tuberoinfundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human. Neuroscience 162:128–147. https://doi.org/10.1016/j.neuroscience.2009.04.054
doi: 10.1016/j.neuroscience.2009.04.054
pubmed: 19401215
Gellén B, Zelena D, Usdin TB, Dobolyi Á (2017) The parathyroid hormone 2 receptor participates in physiological and behavioral alterations of mother mice. Physiol Behav 181:51–58. https://doi.org/10.1016/j.physbeh.2017.09.005
doi: 10.1016/j.physbeh.2017.09.005
pubmed: 28890271
Winer KK (2018) Does PTH replacement therapy improve quality of life in patients with chronic hypoparathyroidism? J Clin Endocrinol Metab 103:2752. https://doi.org/10.1210/JC.2017-02593
doi: 10.1210/JC.2017-02593
pubmed: 29897557
pmcid: 6276667
Winer KK, Ko CW, Reynolds JC et al (2003) Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1–34) versus calcitriol and calcium. J Clin Endocrinol Metab 88:4214–4220. https://doi.org/10.1210/jc.2002-021736
doi: 10.1210/jc.2002-021736
pubmed: 12970289
Vokes TJ, Mannstadt M, Levine MA et al (2018) Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism. J Clin Endocrinol Metab 103:722–731. https://doi.org/10.1210/jc.2017-01471
doi: 10.1210/jc.2017-01471
pubmed: 29099947
Tabacco G, Tay YKD, Cusano NE et al (2019) Quality of life in hypoparathyroidism improves with rhPTH(1–84) throughout 8 years of therapy. J Clin Endocrinol Metab 104:2748–2756. https://doi.org/10.1210/jc.2018-02430
doi: 10.1210/jc.2018-02430
pubmed: 30776291
pmcid: 6530656
Tay D, Cremers S, Bilezikian JP (2018) Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism—translating the pharmacology. Br J Clin Pharmacol 84:252–267
doi: 10.1111/bcp.13455
Khan AA, Rejnmark L, Rubin M et al (2021) PaTH Forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism. J Clin Endocrinol Metab. https://doi.org/10.1210/CLINEM/DGAB577
doi: 10.1210/CLINEM/DGAB577
pubmed: 34922381
pmcid: 8684498